Introduction
============

Oral squamous cell carcinoma (OSCC) is the most commonly diagnosed cancer of the head and neck region, accounting for \~300,000 new cases annually worldwide ([@b1-ol-0-0-6829]). Despite advances in diagnostic, surgical and chemo-radiation techniques, the 5-year survival rates for patients with OSCC have remained at \~50% for the last five decades ([@b2-ol-0-0-6829]). We hypothesize that biological programs, including hypoxia and proliferation, within the tumor microenvironment are associated with tumor progression and may help to identify those patients at greatest risk of relapse and mortality. Identifying those mechanisms and using those factors in clinical decision-making could help target adjuvant therapies and improve the clinical management of patients with OSCC.

Hypoxia is common within the oral tumor microenvironment but rare in normal oral epithelial tissue ([@b3-ol-0-0-6829]). Tumor hypoxia (O~2~ \<5 mmHg) is associated with increased invasiveness, metastasis and an overall poor prognosis ([@b4-ol-0-0-6829]--[@b6-ol-0-0-6829]). Several methods can be used to assess hypoxia within tumors. The direct measurement of tissue oxygen tension, using an oxygen electrode, is highly sensitive but intra-tumoral heterogeneity and the accessibility of tumors, due to anatomical restrictions, limit its utility for the clinical assessment of tumor hypoxia ([@b7-ol-0-0-6829],[@b8-ol-0-0-6829]). Exogenous markers, including bioreductive drugs (e.g., pimonidazole), enable targeted imaging but the threshold for activation by hypoxia may not correspond to clinically-relevant tumor hypoxia, and incomplete distribution due to ineffective perfusion may lead to variability in the reliability of staining across the tumor regions ([@b6-ol-0-0-6829]). Immunohistochemistry (IHC)-based staining for endogenous markers of hypoxia (EMH) is cost effective and routinely available in clinical pathology laboratories; however, no single EMH has been consistently demonstrated to reliably indicate an association with adverse tumor phenotypes and poor prognosis in OSCC ([@b9-ol-0-0-6829]).

While several hypoxic sensitizers and hypoxia-specific toxins are available as potential therapeutic agents, reliably identifying patients with hypoxic tumors for patient selection in the clinical setting is a consistent barrier to implementing effective hypoxia-targeting/sensitizing therapies ([@b6-ol-0-0-6829]). A number of studies have reported associations between a poorer prognosis and intratumoral levels of the EMH carbonic anhydrase IX (CAIX) in several cancer sites, including head and neck squamous cell carcinoma ([@b10-ol-0-0-6829]--[@b14-ol-0-0-6829]). CAIX expression is regulated by hypoxia inducible factor 1-α (HIF1α) ([@b15-ol-0-0-6829]), an oxygen-sensitive transcription factor. The stability and activity of HIF1α are predominantly regulated by intracellular pO~2~ levels; however, elevated transcriptional activation may also occur under normoxic/mildly hypoxic conditions through the stabilization of HIF1α by proliferation-inducing signaling pathways such as phosphatidylinositol 3-kinase (PI3K), nuclear factor-κB (NF-κB), AKT and Her2 ([@b10-ol-0-0-6829],[@b16-ol-0-0-6829]--[@b20-ol-0-0-6829]). Highly hypoxic tumor cells typically exhibit low proliferation ([@b6-ol-0-0-6829],[@b21-ol-0-0-6829],[@b22-ol-0-0-6829]). We previously proposed that the co-localization of proliferation and EMH expression may identify cells responding to proliferative stimuli or EMH regulation by factors other than low pO~2~ ([@b23-ol-0-0-6829]), including alternative signaling pathways that control HIF1α stability and activity ([@b10-ol-0-0-6829],[@b24-ol-0-0-6829]). We had also hypothesized that functionally significant hypoxia would be characterized by low proliferation (low Ki-67 index) within areas of high stromal CAIX (sCAIX) expression ([@b23-ol-0-0-6829]).

Attempts to test these hypotheses led to the observations that sCAIX was more highly associated with patient survival than tumoral CAIX (tCAIX) ([@b13-ol-0-0-6829],[@b14-ol-0-0-6829]), and that there was a strong association between sCAIX^hi^/Ki-67^lo^ protein levels and reduced disease-specific survival (DSS). However, the literature on prognostic biomarkers is replete with association studies that have failed independent replication ([@b25-ol-0-0-6829]). Therefore, the present study aimed to replicate our previous findings in an independent cohort of patients with OSCC.

Materials and methods
=====================

### Patient cohort

The study cohort comprised 168 patients (mean age, 60.6 years; age range, 20--88 years; 93 males, 75 females) diagnosed with histologically confirmed incident primary OSCC treated at the University of Washington Medical Center and the Harborview Medical Center in Seattle between December 2003 and February 2012. The patients were recruited as part of a study conducted at the Fred Hutchinson Cancer Research Center (FHCRC; Seattle, WA, USA) to study genome-wide gene expression associated with the clinical outcomes of patients with OSCC of the oral cavity and oropharynx ([@b26-ol-0-0-6829]). The current study was conducted in accordance with the REMARK guidelines ([@b27-ol-0-0-6829]). The study was conducted following the acquisition of written informed consent and ethical approval from the Institutional Review Office of the Fred Hutchinson Cancer Research Center and the Conjoint Health Research Ethics Board.

### Tissue microarray (TMA) construction

Formalin-fixed paraffin-embedded tumor tissue blocks suitable for analysis, as judged by a pathologist according to tumor content, were obtained for all 168 patients. TMAs were constructed using triplicate 0.6 mm cores from the archived tumor blocks at the FHCRC, and the sections were then shipped to the University of Calgary for IHC staining. Eleven samples of normal oral cavity squamous epithelium from control participants were incorporated in the TMAs as reference samples. Control participants were patients without OSCC who had oral surgery, including tonsillectomy or uvulopalatopharyngoplasty, at the University of Washington Medical Center and the Harborview Medical Center in Seattle between December 2003 and February 2012. Fluorescence IHC and the HistoRx™ Automated Quantitative Analysis (AQUA™) platform AQUAnalysis^®^ software (Genoptix Medical Laboratory, Carlsbad, CA, USA) were used to quantify the expression of CAIX and Ki-67 for each TMA core.

### Quantitative fluorescence IHC

The details of the quantitative fluorescence IHC staining conditions for CAIX, vimentin ([@b14-ol-0-0-6829]) and Ki-67 ([@b28-ol-0-0-6829]) have been described previously. Briefly, the TMA slides were stained on a DAKO AutoStainer Link 48 using antibodies against vimentin (mouse monoclonal; dilution, 1:5,000; catalog no. M0725; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA), CAIX (rabbit polyclonal; dilution, 1:5,000; catalog no. ab15086; Abcam, Cambridge, MA, USA) and pan-cytokeratin (PCK; guinea pig polyclonal; dilution, 1:100; catalog no. BP5069; OriGene Technologies, Inc., Herford, Germany). For Ki-67, the MIB1 mouse monoclonal antibody was used (dilution, 1:7,000; catalog no. M724029-2; Dako; Agilent Technologies, Inc.). Slides were incubated with primary antibodies for 30 min at room temperature. The respective anti-mouse (catalog no. K400111-2) or anti-rabbit (catalog no. K400311-2) secondary antibody polymers (both, EnVision+ System horseradish peroxidase-labelled polymer; undiluted; Agilent Technologies Inc.) were applied for 30 min at room temperature followed by 5 min incubations, again at room temperature, with the following fluorophores: Tyramide-TSA-Plus cysteine (Cy)3 signal amplification reagent (catalog no. NEL744B001KT; PerkinElmer Inc., Waltham, MA, USA), for vimentin detection, and tyramide-Cy5 (TSA-Plus Cy5 signal amplification reagent; catalog no. NEL745B001KT; PerkinElmer Inc.), for CAIX and Ki-67 detection. For PCK detection, slides were incubated with an Alexa 488-conjugated goat anti-guinea pig secondary antibody (catalog no. A11073; dilution, 1:200; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for 30 min at room temperature. All slides were mounted in ProLong Gold Antifade mountant containing DAPI (catalog no. P36935; Thermo Fisher Scientific, Inc.). Slides were scanned using an Aperio ScanScope^®^ FL (Leica Microsystems, Inc., Buffalo Grove, IL, USA) and analyzed using AQUAnalysis^®^ software (version 2.2.1.7). The tumor compartment was defined by the PCK-positive area for each TMA core. The tumor nuclear compartment was defined by the DAPI-positive area within the PCK-positive (tumor) compartment. The Ki-67 compartment was defined by the Ki-67-positive area within the DAPI-positive tumor nuclear compartment ([@b28-ol-0-0-6829]). Finally, the stromal compartment was defined by the combination of the vimentin-positive and PCK-negative areas ([@b29-ol-0-0-6829]). AQUAnalysis^®^ software was used to determine the AQUA scores for sCAIX and tCAIX, as described previously ([@b30-ol-0-0-6829]). Ki-67 expression was calculated from the percentage of the tumor nuclear area (PCK-positive and DAPI-positive) that was Ki-67-positive ([@b28-ol-0-0-6829]).

Basal Ki-67 expression was defined as the lowest level measured amongst triplicate TMA cores for each patient with OSCC; this definition of Ki-67 status was identified to provide the strongest association with 5-year DSS in a prior comparison of Ki-67 scoring strategies ([@b28-ol-0-0-6829]). Conversely, CAIX expression for a given patient was defined using the TMA core that expressed the maximum level of sCAIX among the corresponding triplicate TMA cores. sCAIX was dichotomized at the 75th percentile to identify patients with top-quartile CAIX expression levels in the stromal compartment (sCAIX^hi^) ([@b14-ol-0-0-6829]). Basal Ki-67 expression was dichotomized (percentage of the tumor nuclear area positive for Ki-67) at the median to define the low and high proliferation groups for the proposed replication of the combined Ki-67-sCAIX signature.

### Statistical analysis

The Chi-squared test was used to compare clinical and demographic characteristics between the Calgary and FHCRC cohorts ([Table I](#tI-ol-0-0-6829){ref-type="table"}). The Kaplan-Meier (KM) estimator method and Cox\'s proportional hazards analyses were conducted to assess the association between expression of Ki-67, tCAIX, sCAIX and DSS of patients with OSCC. Univariate Cox proportional hazards analyses were conducted to assess the associations between Ki-67, sCAIX, tCAIX and DSS, as categorical and as continuous variables. Survival was measured from the date of diagnosis to the date of mortality or last follow-up. Data are presented as number of patients and percentage, except for age (mean and standard deviation) ([Table I](#tI-ol-0-0-6829){ref-type="table"}). KM results are presented in survival curves ([Fig. 2](#f2-ol-0-0-6829){ref-type="fig"}). Cox proportional hazards regression results are presented by hazard ratio (HR) and 95% confidence interval (CI; [Table II](#tII-ol-0-0-6829){ref-type="table"}). The threshold for statistical significance was set at P\<0.05 or where CIs excluded unity. Multivariable Cox proportional hazards analyses were conducted to assess the impact of clinically significant covariates, including age, sex and American Joint Committee on Cancer stage. All statistical analyses (KM, Cox proportional hazards and χ^2^) were performed using Stata 14 (StataCorp LP, College Station, TX, USA). Optimized threshold values for Ki-67, sCAIX and tCAIX were determined using the X-Tile software^®^ (version 3.6.1; Rimm Labs, New Haven, CT, USA) ([@b31-ol-0-0-6829]).

Results
=======

### Cohort characteristics

The mean age for patients included in the present study was 60.3 years \[standard deviation (SD), 14.0; range, 20--88 years\]. The median follow-up time for the cohort was 33 months (range, 0.2--111.0 months). The results of univariate analyses of cohort clinicopathological characteristics are presented in [Table I](#tI-ol-0-0-6829){ref-type="table"}.

### Biomarker expression analysis

CAIX and Ki-67 expression levels were successfully quantified for 168/189 tumors; the data on the remaining 21 tumors were absent due to tissue processing defects, such as folded sections, and insufficient quantities of tumor tissue identified during quality control for each individual TMA core image. Images representing typical fluorescence IHC patterns for each biomarker are presented in [Fig. 1](#f1-ol-0-0-6829){ref-type="fig"}. CAIX staining intensity was highest in the membranous or cytoplasmic regions in the tumor and stromal compartments ([Fig. 1A](#f1-ol-0-0-6829){ref-type="fig"}). Tumor Ki-67 expression was predominantly restricted to the nucleus ([Fig. 1B](#f1-ol-0-0-6829){ref-type="fig"}). Proliferative (Ki-67-positive) cells were observed in the tumoral and stromal compartments.

sCAIX and tCAIX were observed to be associated with reduced DSS ([Table II](#tII-ol-0-0-6829){ref-type="table"}). Elevated sCAIX was associated with DSS when analyzed as a continuous variable in univariate and adjusted analyses (HR, 1.014 and 95% CIs, 1.003--1.024; HR, 1.010 and 95% CIs, 1.001--1.019, respectively). Additionally, elevated tCAIX was associated with reduced DSS when analyzed as a continuous variable in univariate and adjusted analyses (HR, 1.003 and 95% CIs, 1.001--1.006; HR, 1.002 and 95% CIs, 1.000--1.0005, respectively). High tCAIX was also observed to be associated with reduced DSS in univariate and adjusted analyses when dichotomized at the 75th percentile (HR, 2.19 and 95% CIs, 1.25--3.83; HR, 1.99 and 95% CIs, 1.13--3.50, respectively). The clinical and demographical characteristics of patients in the tCAIX^hi^ group did not differ significantly from those in the tCAIX^lo^ group, for the majority of the parameters. However, those in the tCAIX^hi^ group were more likely to have larger tumors (higher pathological tumor stage) and have nodal metastases (positive pathological nodal status; [Table III](#tIII-ol-0-0-6829){ref-type="table"}). sCAIX was not significantly associated with reduced DSS when dichotomized at the 75th percentile. In contrast to our prior reports ([@b23-ol-0-0-6829],[@b28-ol-0-0-6829]), low basal Ki-67 was not associated with reduced DSS when analyzed as a continuous variable in univariate or adjusted analyses (adjusted HR, 1.01; 95% CIs, 0.99--1.02).

Subsequently, exploratory analyses were conducted to determine an optimized threshold value for Ki-67, sCAIX and tCAIX using the X-Tile software^®^ ([@b28-ol-0-0-6829]); the optimized threshold value is the threshold of Ki-67, sCAIX and tCAIX that is associated with the greatest difference in the HR for DSS between the dichotomized groups. Basal Ki-67 values ranged from 0.9--79.3 (mean, 26.5; SD, 17.7; median, 23.7), and the optimized cut-off point was set at 48.5. Applying this cut-off point suggested an increased risk (adjusted HR, 2.17, 95% CIs, 1.08--4.38) associated with high Ki-67 (\>48% tumor nuclear area; [Fig. 2A and B](#f2-ol-0-0-6829){ref-type="fig"}). Only 19/168 patients (11.3%) exhibited Ki-67 positivity in \>48.5% of the nuclear area. tCAIX values ranged from 6.1--377.1 (mean, 98.0; SD, 92.7; median, 63.2). The optimal cut-off point for tCAIX was at 176.7 (adjusted HR, 2.45; 95% CIs, 1.40--4.31); 33/168 tumors (\~20%) expressed tCAIX above this value ([Fig. 2C and D](#f2-ol-0-0-6829){ref-type="fig"}). sCAIX values ranged from 4.8--127.58 (mean, 28.6; SD, 23.3; median, 20.8). The optimal cut-off point for sCAIX was set at 54.8 (adjusted HR, 2.39 95% CIs, 1.22--4.67; [Fig. 2E and F](#f2-ol-0-0-6829){ref-type="fig"}); 17/168 tumors (\~10%) expressed sCAIX above this value.

### Non-replication of the 'functional hypoxia' (combined sCAIX and Ki-67 expression) signature

In our prior report ([@b23-ol-0-0-6829]), stratification of sCAIX^hi^-expressing tumors according to their median basal Ki-67 expression identified patients with significantly poorer 5-year DSS (HR, 7.2; 95% CIs, 2.5--20.4). However, tumors defined by combined sCAIX^hi^ and Ki-67^lo^ were not associated with reduced 5-year DSS in the FHCRC cohort in univariate or adjusted analyses (HR, 1.43 and 95% CIs, 0.69--2.97; HR, 1.18 and 95% CIs, 0.59--2.41, respectively).

Discussion
==========

Our previous study demonstrated, in two independent cohorts, that sCAIX was more highly associated with patient survival than tCAIX ([@b13-ol-0-0-6829],[@b14-ol-0-0-6829]). In the current study, elevated sCAIX and tCAIX were associated with reduced DSS when analyzed as continuous variables, but only tCAIX was associated with DSS when dichotomized at the 75th percentile. The association between sCAIX and DSS, when analyzed as a continuous variable but not as a categorical variable, suggests that sCAIX may be a biologically important factor in OSCC survival but also that the 75% cut-off point is not appropriate for clinical decision making.

The association between DSS and sCAIX and tCAIX, for each unit increase in expression (AQUA score), was similar (sCAIX: HR, 1.014, 95% CIs, 1.003--1.024 vs. tCAIX: HR, 1.003, 95% CIs, 1.001--1.006). The increased risks associated with each measure of CAIX expression were also similar when dichotomized at their optimized cut points (sCAIX adjusted HR, 2.39, 95% CIs, 1.22--4.67; tCAIX adjusted HR, 2.45, 95% CIs, 1.40--4.31). However, the group defined by the optimized cut-off point for tCAIX contained almost twice as many patients, compared with the group defined by the optimized cut-off point for sCAIX. The strength of the association with DSS was similar for each dichotomized measure of CAIX, suggesting that, tCAIX is a more informative prognostic marker than sCAIX. Determining which of the two, tCAIX or sCAIX, is the more informative measure of tumor CAIX status and defining a biologically meaningful expression threshold remains a necessary step if this marker is to be translated into a clinically useful test.

Our prior study reported the prognostic impact of a combined sCAIX/Ki-67 signature on DSS in OSCC ([@b23-ol-0-0-6829]). This signature was proposed on the basis of the potential confounding effect of proliferation, and associated signaling pathways, on the association between CAIX expression and prognosis. This was a logical extension of our previous research, reporting significantly reduced survival in patients with high sCAIX and low Ki-67, separately ([@b14-ol-0-0-6829],[@b28-ol-0-0-6829]). The current study did not replicate this proposed 'functional hypoxia' signature according to our original definitions of low Ki-67 and high sCAIX. The association between DSS and each component of the functional hypoxia signature was then further examined. The failure of each individual component may explain the lack of association detected in the proposed 'functional hypoxia' signature. In contrast to prior reports ([@b14-ol-0-0-6829],[@b23-ol-0-0-6829]), sCAIX was not significantly associated with survival when dichotomized at the 75th percentile in univariate and adjusted analyses (HR, 1.36 and 95% CIs, 0.74--2.51; HR, 1.23 and 95% CIs, 0.68--2.23, respectively). Furthermore, when Ki-67 was analyzed as a continuous variable, there was no association with reduced survival in univariate or adjusted analyses (HR, 1.009 and 95% CIs, 0.995--1.023; HR, 1.009 and 95% CIs, 0.995--1.024, respectively) in the current study.

Hypoxic tumors are typically associated with a poor prognosis; not all tumors are considered to be hypoxic, but a high proportion of tumors have areas of hypoxia and tumors which exhibit increased hypoxia typically have poorer outcomes ([@b22-ol-0-0-6829],[@b32-ol-0-0-6829]). The potential role for hypoxia and proliferation in the prognosis of OSCC, and other types of head and neck cancer, has been investigated by a number of research groups ([@b33-ol-0-0-6829]--[@b35-ol-0-0-6829]). Recently, there has been particular interest in the role of CAIX in the stroma as it should not be confounded by somatic gene alterations commonly observed in OSCC. For example, the von Hippel-Lindau (*VHL*) gene, a negative regulator of HIF1α activity, is commonly deleted in OSCC ([@b36-ol-0-0-6829]). The loss of VHL leads to an accumulation of HIF1α and drives the hypoxia-independent expression of CAIX ([@b37-ol-0-0-6829],[@b38-ol-0-0-6829]). However, proliferation-associated factors may also enhance sCAIX expression despite the absence of hypoxia. The response of tumor cells to proliferative signaling in the tumor microenvironment is likely to be most relevant to the disease course. Consequently, we assigned proliferation status of the tumor/patient based on the measurement of Ki-67 in the PCK-positive tumor cell compartment. However, paracrine/autocrine growth factor signaling within the tumor microenvironment may contribute to HIF1α stabilization in the tumor stroma, and elevate sCAIX expression independent of hypoxia. Furthermore, local depletion of oxygen and nutrients due to the high tumor cell density may induce peri-cellular hypoxia and consequent elevation in sCAIX expression ([@b10-ol-0-0-6829],[@b39-ol-0-0-6829]).

The cohorts of oral cancer patients from Calgary and FHCRC are broadly similar when comparing common clinical and demographic characteristics ([Table II](#tII-ol-0-0-6829){ref-type="table"}). Therefore, the failure to replicate the previous combined Ki-67-sCAIX association cannot be solely attributed to differences in these populations. However, the limitation of the sub-group sizes and post hoc definition of survival groups in the original report is acknowledged, and emphasizes the requirement for replication in an independent OSCC cohort.

Several mRNA-based multi-parameter prognostic and predictive assays have been proposed for head and neck cancer and for other cancer types, particularly breast cancer ([@b5-ol-0-0-6829],[@b40-ol-0-0-6829]--[@b42-ol-0-0-6829]). However, due to logistical and cost challenges, few gene expression-based tests are currently in routine clinical use for treatment selection. IHC-based assays, for the purposes of diagnosis and prognostication, are appealing as standard clinical pathology laboratories are equipped to conduct these assays. Recent evidence suggests that the IHC-based tests provide similar assessments of recurrence risk in patients with breast cancer, so the potential to develop an equivalent test in patients with OSCC is present ([@b43-ol-0-0-6829]).

The current study adhered to the REMARK criteria for the reporting of prognostic studies ([@b27-ol-0-0-6829]). The present study was limited by its retrospective design and the lack of corroborative measures of intra-tumoral hypoxia, such as directly measured pO~2~ or pimonidazole distribution. Our results support the role of CAIX in OSCC survival but the relative importance of sCAIX or tCAIX is unclear. The addition of proliferation markers, such as Ki-67, could potentially improve the prognostic utility of sCAIX or tCAIX, but the present study was unable to replicate the prior findings ([@b23-ol-0-0-6829]). Studies in larger cohorts of patients with OSCC could enable the derivation of prognostic signatures for OSCC or the identification of specific hypoxia-sensitizing/targeting treatments ([@b44-ol-0-0-6829]).

The current study was supported by a grant from the US National Cancer Institute, National Institutes of Health (grant no. RO1CA 095419), with additional funds from the Fred Hutchinson Cancer Research Center and the Ohlson Research Initiative in Head and Neck Cancer Research.

![Fluorescent immunohistochemical staining imaged with an Aperio ScanScope FL^®^ and analyzed using AQUAnalysis^®^ software. Indicated are representative fluorescence immunohistochemistry images of (A and B) CAIX and (C and D) Ki-67 staining in OSCC samples. (A) Positive and negative controls for CAIX involved the staining of normal OSCE with/and without the CAIX antibody, respectively. (C) Similarly, positive and negative controls for Ki-67 involved the staining of tonsil tissue with or without the Ki-67 antibody, respectively. Representative images of OSCC samples stained for (B) CAIX and (D) Ki-67 are indicated with examples of high and low expressers of these proteins. Merged images are pseudo-colored blue for DAPI, green for pan-cytokeratin, red for the biomarker of interest and grayscale for vimentin. OSCE, oral squamous cell epithelium; OSCC, oral squamous cell carcinoma; AQUA, Automated Quantitative Analysis™; CAIX, carbonic anhydrase IX; s, stromal.](ol-14-05-5434-g00){#f1-ol-0-0-6829}

![Frequency distributions of AQUA^®^ scores in OSCC patients and Kaplan-Meier survival curves according to the optimized AQUA^®^ score cut-off points derived using X-Tile^®^ software. (A) Frequency distribution histogram for Ki-67 AQUA^®^ scores. (B) Frequency distribution histogram for sCAIX AQUA^®^ scores. (C) Frequency distribution histogram for tCAIX AQUA^®^ scores. (D) Kaplan-Meier survival curve according to optimized threshold value for Ki-67 AQUA^®^ scores. (E) Kaplan-Meier survival curve according to optimized threshold value for sCAIX AQUA^®^ scores. (F) Kaplan-Meier survival curve according to optimized threshold value for tCAIX AQUA^®^ scores. OSCC, oral squamous cell carcinoma; AQUA, Automated Quantitative Analysis™; CAIX, carbonic anhydrase IX; t, tumoral, s, stromal.](ol-14-05-5434-g01){#f2-ol-0-0-6829}

###### 

Comparison between clinicopathological and demographical characteristics of the Calgary and FHCRC cohorts.

                                   Calgary (n=121)   FHCRC (n=168)                        
  -------------------------------- ----------------- --------------- ------------- ------ -----------------------------------------------
  Sex                                                                                     0.03
    Male                           82                67.8              93          55.4   
    Female                         39                32.2              75          44.6   
  Age                                                                                     
    Years (mean, SD)               60.6 (13.5)                       60.3 (14.0)          
  History of tobacco smoking                                                              0.34
    Never                          28                23.1              48          28.6   
    Ever                           91                75.2            120           71.4   
    Missing                          2               1.7                                  
  History of alcohol consumption                                                          0.39
    Never                          13                10.7              21          12.5   
    Ever                           65                53.7            146           86.9   
    Missing                        43                35.5              1           0.6    
  pT status                                                                               0.80
    pT1/pT2 (low)                  70                57.9              96          57.1   
    pT3/pT4 (high)                 48                39.7              70          41.7   
    Missing                          3               2.5               2           1.2    
  pN status                                                                               0.10
    N0 neck                        75                62.0              88          52.4   
    N+ neck                        46                38.0              80          47.6   
  Tumor differentiation                                                                   
    Well                           18                14.9              35          20.8   0.36
    Moderate                       60                49.6              90          53.6   
    Poor                           14                11.6              34          20.2   
    Missing                        29                24.0              9           5.4    
  Oral cavity subsite                                                                     0.10
    Oral tongue                    49                40.5              63          37.5   
    Floor of mouth                 32                26.4              39          23.2   
    Buccal                         17                14.0              14          8.3    
    Gingiva                        13                10.7              37          22.0   
    Others/site NOS                10                8.3               15          8.9    
  Treatment                                                                               ^[a](#tfn1-ol-0-0-6829){ref-type="table-fn"}^
    Surgery alone                  38                31.4              69          41.1   
    Surgery + RT                   83                68.6              40          23.8   
    Surgery + chemo + RT                                               52          31.0   
    Surgery + chemo                                                    2           1.2    
    Incomplete data                                                    5           3.0    

Missing data were excluded from the χ^2^ test.

Not calculated. FHCRC, Fred Hutchinson Cancer Research Centre; RT, radiotherapy; NOS, not otherwise specified.

###### 

Summary of univariate and multivariate Cox proportional hazards analysis of OSCC DSS.

  Biomarker                     Analysis                         Hazard ratios, (95% CIs)
  ----------------------------- -------------------------------- --------------------------
  sCAIX (continuous)            Univariate                       1.014, (1.003--1.024)
                                Adjusted (age, sex and stage)    1.010, (1.001--1.019)
  tCAIX (continuous)            Univariate                       1.003, (1.001--1.006)
                                Adjusted (age, sex and stage)    1.002, (1.000--1.0005)
  Ki67 (continuous)             Univariate                       1.009, (0.995--1.023)
                                Adjusted (age, sex and stage)    1.009, (0.995--1.024)
  tCAIX (dichotomized, 75%)     Univariate                       2.19, (1.25--3.83)
                                Adjusted (age, sex and stage)    1.99, (1.13--3.50)
  sCAIX (dichotomized, 75%)     Univariate                       1.36, (0.74--2.51)
                                Adjusted (age, sex and stage)    1.23, (0.68--2.23)
  Ki67 (dichotomized, median)   Univariate                       1.23, (0.73--2.06)
                                Adjus.ted (age, sex and stage)   1.29, (0.75--2.21)

OSCC, oral squamous cell carcinoma; CAIX, carbonic anhydrase IX; s, stromal; t, tumoral; CI, confidence interval; DSS, disease-specific survival.

###### 

Comparison of clinical and demographic features between patient groups stratified by tCAIX (\<75th vs. ≥75th percentiles).

                                   Low tCAIX (n=126)   High tCAIX (n=42)                        
  -------------------------------- ------------------- ------------------- ------------- ------ ----------------------------------------------------
  Sex                                                                                           0.929
    Male                             70                55.6                23            54.8   
    Female                           56                44.4                19            45.2   
  Age                                                                                           
    Years (mean, SD)               60.8 (14.4)                             58.5 (13.0)          
  History of tobacco smoking                                                                    0.115
    Never                            32                25.4                16            38.1   
    Ever                             94                74.6                26            61.9   
  History of alcohol consumption                                                                0.144
    Never                            13                10.3                  8           19.1   
    Ever                           112                 88.9                34            80.9   
    Missing                          1                 0.8                                      
  pT status                                                                                     0.019a
    pT1/pT2 (low)                    80                63.5                18            42.9   
    pT3/pT4 (high)                   46                36.5                24            57.1   
    Missing                          0                 0.0                   0           0.0    
  pN status                                                                                     0.004^[a](#tfn4-ol-0-0-6829){ref-type="table-fn"}^
    N0 neck                          74                58.7                14            33.3   
    N+ neck                          52                41.3                28            66.7   
  Tumor differentiation                                                                         0.170
    Well                             30                23.8                  5           11.9   
    Moderate                         64                50.8                26            61.9   
    Poor                             23                18.3                11            26.2   
    Missing                          9                 7.1                   0           0.0    
  Oral cavity subsite                                                                           0.068
    Oral tongue                      46                36.5                17            40.5   
    Floor of mouth                   25                19.8                14            33.3   
    Buccal                           9                 7.1                   5           11.9   
    Gingiva                          32                25.4                  5           11.9   
    Others/site NOS                  14                11.1                  1           2.4    
  Treatment                                                                                     0.032a
    Surgery alone                    58                46.0                11            26.2   
    Surgery + RT                     31                24.6                  9           21.4   
    Surgery + chemo + RT             32                25.4                20            47.6   
    Surgery + chemo                  1                 0.8                   1           2.4    
    Incomplete data                  4                 3.2                   1           2.4    

P\<0.05. OSCC, oral squamous cell carcinoma; CAIX, carbonic anhydrase IX; s, stromal; t, tumoral; CI, confidence interval; DSS, disease-specific survival; RT, radiotherapy; NOS, not otherwise specified.
